Savara awarded promising innovative medicine (pim) designation in the united kingdom (uk) for molgramostim nebulizer solution (molgramostim) in autoimmune pulmonary alveolar proteinosis (apap)

Austin, texas--(business wire)--savara inc. (nasdaq: svra), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the uk's medicines and healthcare products regulatory agency (mhra) granted promising innovative medicine (pim) designation to molgramostim for the treatment of apap, a rare lung disease with no approved pharmaceutical treatments. pim designation is an early indication that molgramostim is a promising candidate for the eams, a program
SVRA Ratings Summary
SVRA Quant Ranking